ライフサイエンスコーパス: unacceptable

1 re a kappa value of less than 0.5 was deemed unacceptable.

2 ional transistor-based logic gates, which is unacceptable.

3 uffering of any significant degree should be unacceptable.

4 re or, worse still, catastrophic fracture is unacceptable.

5 in access to affordable cancer treatment is unacceptable.

6 ication and 13% of toxigenicity reports were unacceptable.

7 ocated to pseudoplacebo to risks that may be unacceptable.

8 iated toxic effects of chemoradiation can be unacceptable.

9 eutic termination of affected pregnancies is unacceptable.

10 that are otherwise clinically stable may be unacceptable.

11 ce a calibration model whose performance was unacceptable.

12 gh side effects in gynecological tissues are unacceptable.

13 using donors who were previously considered unacceptable.

14 ciency virus and noncommunicable diseases is unacceptable.

15 e variables were scored as acceptable (1) or unacceptable (0); the overall panel performance score fo

16 multaneous matrix effect, this could lead to unacceptable accuracy in quantitative liquid chromatogra

17 owed significant improvements but still with unacceptable accuracy.

18 ts were treated until progressive disease or unacceptable adverse effects occurred.

19 pment or been removed from the market due to unacceptable adverse effects.

20 t was continued until disease progression or unacceptable adverse effects.

21 lenalidomide until disease progression or an unacceptable adverse event (AE) occurred.

22 e decitabine until disease progression or an unacceptable adverse event occurred.

23 (10 mg daily) until disease progression, an unacceptable adverse event, or completion of 12 cycles.

24 (2) every 14 or 21 days until progression or unacceptable adverse events (AEs).

25 ng placebo on days 2-21, every 3 weeks until unacceptable adverse events or disease progression.

26 2 mg once per day until disease progression, unacceptable adverse events, consent withdrawal, or deat

27 ous 21-day cycles until disease progression, unacceptable adverse events, withdrawal of consent, or d

28 cence intensity [MFI]) were determined to be unacceptable and entered into the United Network for Org

29 enefits of biotechnology are enjoyed without unacceptable and irreversible environmental costs.

30 stance to the used antibiotics, results were unacceptable and, at least for CLARI, are influenced by

31 cross-matches were positive, 20 donors were unacceptable, and 22 recipients had unacceptably high do

32 We understand that this is unacceptable, and deeply apologize to Drs.

33 o produce new agents based on this notion is unacceptable, and there is an increasing need for altern

34 h quality mechanisms and are contributing to unacceptable-and unsustainable-levels of irreproducibili

35 class II (98% vs. 69%) cPRA levels and more unacceptable antigens (32 vs. 8).

36 tunity for XM based on serologically defined unacceptable antigens can disadvantage the patient.

37 ding to local procedures required listing as unacceptable antigens for organ allocation.

38 ns targeted by denatured HLA antibodies from unacceptable antigens lowered the calculated panel react

39 levels and any change in the mean number of unacceptable antigens or their mean fluorescence intensi

40 s at once, and with and without exclusion of unacceptable antigens selected to give a virtual calcula

41 DQ serologic specificities can be entered as unacceptable antigens, they are assigned only by the ide

42 in EpMM was larger when CPs were listed with unacceptable antigens.

43 more than 10,000 for HLA-DQ were reported as unacceptable antigens.

44 o be a valuable alternative to better define unacceptable antigens.

45 The unacceptable apathy of governments and funders of global

46 ge at 150 mAs, above average at 100 mAs, and unacceptable at 50 mAs.

47 whether the alignment provided acceptable or unacceptable attenuation-corrected PET images.

48 productivity dilemma of long cycle times and unacceptable attrition rates in the preclinical drug dis

49 publications of the same data are considered unacceptable because they undermine the public confidenc

50 beings, and randomisation would be ethically unacceptable because vascular protection would have to b

51 sed P-values to estimate the FDR can produce unacceptable bias in those estimates.

52 omarkers of atherothrombosis without causing unacceptable bleeding in patients undergoing surgery for

53 omarkers of atherothrombosis without causing unacceptable bleeding.

54 without undue risk for adverse events or an unacceptable burden on patients.

55 treatment decisions that would be considered unacceptable by pain specialists.

56 ous neuropsychiatric effects that was deemed unacceptable by regulatory authorities, and both the dru

57 insemination or inducing oestrus was judged "unacceptable" by 69% and 48% of practitioners, respectiv

58 Because of the unacceptable complications associated with open cholecys

59 The highest dose level induced unacceptable constitutional symptoms.

60 whereas the avian and human assays exhibited unacceptable cross-reactions with feces from other hosts

61 stration of imatinib was not associated with unacceptable cumulative or late toxic effects.

62 ) using deuterium versus (15)N labeling gave unacceptable differences (>15%) upon quantifying some of

63 nsplantation and may allow identification of unacceptable donor antigens, or patients who may require

64 which will lead to better representation of unacceptable DQ alleles and improve organ allocation equ

65 ly twice daily until tumor progression or an unacceptable drug-related toxicity occurred.

66 cond type of insulin if hyperglycemia became unacceptable during the first year of the study or subse

67 e treatments for this disease are poor, with unacceptable efficacy and safety profiles, particularly

68 first and second-line triple treatments have unacceptable eradication rates in the central region of

69 < or =14 mm) to Acinetobacter spp. led to an unacceptable error rate (23.3%).

70 during plasma sample preparation resulted in unacceptable error that precluded direct measurement of

71 e cell or in vivo imaging, and this leads to unacceptable errors when analysing data on a pixel-wise

72 an result in significant toxicities and have unacceptable failure rates.

73 There was an unacceptable false-negative rate for HER2 status with GH

74 f these undesirable characteristics and were unacceptable for clinical evaluation.

75 licensed vaccine strains used in animals are unacceptable for human use due to undesirable side effec

76 Unfortunately, PRANK still had a high, and unacceptable for most applications, false positives rate

77 the images in the three groups were rated as unacceptable for noise (P < .001).

78 Simple permutation of disease status is unacceptable for resolving this issue because the replic

79 eath gas rates and REE (R(2) ~ 0.9) but were unacceptable for RQ (R(2) = 0.3), Gox, and Fox (R(2) = 0

80 it presents a level of risk that has become unacceptable for the current population.

81 such high rates of unfavorable outcomes are unacceptable; future research is needed to identify ways

82 f lapatinib dose reduction, mostly caused by unacceptable grade 3 diarrhea.

83 icity and its omission (0 mg/kg) resulted in unacceptable graft failure (three of three patients had

84 r Disease in the UK, which aim to reduce the unacceptable harmful consequences of excess alcohol cons

85 trogen-containing contraceptives confers an "unacceptable health risk" during established anticoagula

86 ction strategy to address what it considered unacceptable health risks and an insufficient regulatory

87 Unacceptable hematologic toxicity (UHT) was defined as m

88 on in Poland enabled the otherwise ethically unacceptable, hence unavailable, comparison of the perio

89 or T and B cell and by method of identifying unacceptable HLA antigens and crossmatch techniques.

90 In addition, using actual patients' unacceptable HLA antigens, the number of compatible dono

91 pective crossmatching to exclude donors with unacceptable HLA antigens.

92 ch as a function of a transplant candidate's unacceptable HLA antigens.

93 ate the accuracy with which the detection of unacceptable human leukocyte antigen (HLA) antigens by m

94 zes, and image noise levels that resulted in unacceptable image quality and artifact rankings (score

95 Studies with unacceptable image quality were excluded.

96 gens they target should not be considered as unacceptable in most cases, because they negatively impa

97 is large retrospective analysis confirms the unacceptable incidence of TEEs in patients receiving cis

98 ombotic effects than clopidogrel, without an unacceptable increase in hemorrhagic or other side effec

99 a significant loss in distance acuity or an unacceptable increase in visual symptoms.

100 and improve function of initially otherwise unacceptable injured donor lungs followed by transportat

101 rization in vivo, compound 1 demonstrated an unacceptable level of brain penetration.

102 als, early stopping rules that identified an unacceptable level of cardiotoxicity were never reached.

103 An unacceptable level of GI toxicity in the first 15 patien

104 to 3 years or until disease recurrence or an unacceptable level of toxic effects occurred.

105 All systems tested exhibited a high, unacceptable level of very major (false-susceptible) err

106 Unacceptable levels of error (minor, major, and very maj

107 Unacceptable levels of Mycobacterium tuberculosis transm

108 el of inappropriate cross-talk could lead to unacceptable levels of noise or interference in signal t

109 ver have so far demonstrated significant and unacceptable levels of non-targeted methylation.

110 urability, stability, lack of effectiveness, unacceptable levels of tolerability or safety concerns.

111 use in animals elicit protection but retain unacceptable levels of virulence.

112 of the potent immunogenic adjuvants display unacceptable local or systemic reactogenicity.

113 mon 2-stage design to distinguish between an unacceptable (</=10%) and an acceptable (>/=30%) respons

114 tant gram-negative bacilli continue to cause unacceptable morbidity and mortality rates.

115 amenable to PN or for whom PN may result in unacceptable morbidity even when performed at centers wi

116 Infectious pneumonias exact an unacceptable mortality burden worldwide.

117 an alternative to the increasingly ethically unacceptable mouse bioassay.

118 FBP had unacceptable noise at 40 and 75 mAs in 17 and five patie

119 rvation has been made that there might be an unacceptable number of false-positive enzyme immunoassay

120 nts were generally grade 1 or 2; however, an unacceptable number of patients in the brentuximab vedot

121 limits setting the type I/II error rates and unacceptable odds ratios (ORs) for the outcomes being st

122 d overall diagnostic confidence changed from unacceptable on FBP to acceptable on ASIR images.

123 However, unacceptable percentages of very major errors (false sus

124 es needed further investigation for possible unacceptable performance, even according to the least-st

125 uld not currently gain acceptance in view of unacceptable perimetric standards and equivocal results.

126 ering events were caused by controversial or unacceptable physician behavior.

127 clinicians will continue to be placed in the unacceptable position of not knowing if and when to admi

128 iled the industry acceptance criteria due to unacceptable positive bias for the middle and high quali

129 If so, then perhaps we can eliminate the unacceptable premature morbidity and mortality associate

130 configuration resulted in fewer images with unacceptable quality than did the 64 x 0.6-mm configurat

131 Unacceptable radiotherapy protocol deviations (ie, inapp

132 range (kappa = 0.20-0.39), and three in the unacceptable range (kappa values,0.20).

133 OLFOX6 with bevacizumab did not result in an unacceptable rate of obstruction, perforation, bleeding,

134 ical site infections continue to occur at an unacceptable rate, annually costing billions of dollars

135 rawal trials in heterogeneous cohorts showed unacceptable rates of acute rejection (AR), we hypothesi

136 study was terminated prematurely because of unacceptable rates of AR (4 of 14) and/or de novo DSAs (

137 ine for those at highest risk, could end the unacceptable relationship between CKD and disadvantage i

138 ighteen cases (45%) were considered to be at unacceptable risk for infection transmission.

139 ulatory community highlighted significant or unacceptable risk of ARs to nontarget wildlife, use of S

140 er to the program (</=1:256), because of the unacceptable risk of exposing patients with higher titer

141 tic cold storage (SCS) is associated with an unacceptable risk of primary nonfunction and delayed gra

142 ng in a woman with a breast mass presents an unacceptable risk to her fetus.

143 hom an allogeneic procedure could present an unacceptable risk.

144 ion of chronic allograft rejection and carry unacceptable risks including toxicity, neoplasia, and li

145 e real benefits and where there are real and unacceptable risks to patients and staff.

146 ultimately found to offer poor value or have unacceptable risks.

147 p for whom current smallpox vaccines have an unacceptable safety profile.

148 h dehydration resulted in tough textures and unacceptable sensory qualities for process I samples.

149 respecified primary outcomes were absence of unacceptable serious adverse events (safety), continued

150 7 patients with an inadequate response to or unacceptable side effects associated with one or more tu

151 ponse (51% of patients with resistance to or unacceptable side effects from dasatinib or nilotinib an

152 CML or Ph-positive ALL with resistance to or unacceptable side effects from dasatinib or nilotinib or

153 nts who had an inadequate response to or had unacceptable side effects from hydroxyurea, ruxolitinib

154 era who had an inadequate response to or had unacceptable side effects from hydroxyurea.

155 who had not had a response to or who had had unacceptable side effects from prior therapies.

156 of potent adjuvant molecules that can cause unacceptable side effects in prophylactic vaccination.

157 ients in whom conventional therapy failed or unacceptable side effects occurred.

158 ain is limited by marginal effectiveness and unacceptable side effects of current drugs.

159 lable in oral form, is associated with fewer unacceptable side effects than amphotericin, and is wide

160 opathic pain deliver inadequate pain relief, unacceptable side effects, or both.

161 f tariquidar would likely be associated with unacceptable side effects.

162 e drugs that broadly target the pathway have unacceptable side effects.

163 ned antidyskinetic benefit in the absence of unacceptable side effects.

164 ression otherwise required would likely have unacceptable side effects.

165 oach, but the agents tested to date have had unacceptable side effects.

166 mor necrosis factor (TNF) antagonists or had unacceptable side effects.

167 remission, or time to drug withdrawal due to unacceptable side-effects or to lack of seizure control.

168 Several agents have caused harm or unacceptable side-effects.

169 This unacceptable situation has stimulated research for new d

170 hip, are still our best chance to change the unacceptable status quo of the tuberculosis situation wo

171 bstitution is poorly tolerated, and to avoid unacceptable steric interactions, these compounds adopt

172 OAB, but development was discontinued due to unacceptable structure-based toxicity in preclinical spe

173 hypertrophic cardiomyopathy (HCM) who are at unacceptable surgical risk.

174 er agent in human clinical trials because of unacceptable systemic toxicity.

175 d (r=0.38, rho=0.41, ICC=0.17), resulting in unacceptable therapeutic decision agreement (kappa=0.38)

176 oxicity, and a drug class associated with an unacceptable therapeutic index.

177 nwhile, temozolomide and thalidomide carries unacceptable thrombosis risk.

178 tality rate of the disease, it was ethically unacceptable to allocate patients from within the same f

179 ol or who found the side effects of ursodiol unacceptable to receive obeticholic acid at a dose of 10

180 upport, would have a quality of life that is unacceptable to the candidate or are likely to be noncom

181 hen reconstruction is not feasible or proves unacceptable to the injured patient.

182 <50%, <70%, <99%, 100%) and image quality (1[unacceptable] to 5[excellent]).

183 py every 3 months until disease progression, unacceptable toxic effect, or death.

184 hout treatment), until tumour progression or unacceptable toxic effects arose.

185 re treated every 3 weeks till progression or unacceptable toxic effects for up to six cycles.

186 n 28-day cycles until disease progression or unacceptable toxic effects occurred (elotuzumab was give

187 weeks for 24 months or until progression or unacceptable toxic effects occurred.

188 nd were treated until disease progression or unacceptable toxic effects of the drug occurred.

189 st 24 weeks followed by antibody alone until unacceptable toxic effects or disease progression occurr

190 re treated once every 3 weeks until they had unacceptable toxic effects or their disease progressed.

191 adverse events until disease progression or unacceptable toxic effects), with assessments on day 1 o

192 ntil disease progression, the development of unacceptable toxic effects, or a complete response was d

193 IRI every 2 weeks until disease progression, unacceptable toxic effects, or death.

194 aily continuously until disease progression, unacceptable toxic effects, or patient withdrawal for up

195 mab every 2 weeks until disease progression, unacceptable toxic effects, or the end of the study (ie,

196 ry 2 weeks until disease progression, death, unacceptable toxic effects, or withdrawal from study.

197 ven every 3 weeks until disease progression, unacceptable toxic effects, or withdrawal of consent.

198 lacebo, until progression, the occurrence of unacceptable toxic effects, or withdrawal of consent.

199 in 21 day cycles until disease progression, unacceptable toxic effects, voluntary withdrawal by the

200 il disease progression or the development of unacceptable toxic effects.

201 s 28-day cycles until disease progression or unacceptable toxic effects.

202 curve 6 every 3 weeks) until progression or unacceptable toxic effects.

203 (3 mg/kg) every 2 weeks until progression or unacceptable toxic effects.

204 of chemotherapy until disease progression or unacceptable toxic effects.

205 to 18 months or until disease progression or unacceptable toxic effects.

206 y 2 weeks) administered until progression or unacceptable toxic effects.

207 (560 mg) daily until progressive disease or unacceptable toxic effects.

208 til the occurrence of disease progression or unacceptable toxic effects.

209 /kg every 6 weeks until disease progression, unacceptable toxicities, or withdrawal of consent.

210 after 6 months of induction chemotherapy but unacceptable toxicities, radiation therapy may be offere

211 py can continue until time of progression or unacceptable toxicities.

212 onspecific T cell activation have clinically unacceptable toxicities.

213 ide maintenance until disease progression or unacceptable toxicity (MPT-T) and the same MP regimen wi

214 21 of 28 days until lymphoma progression or unacceptable toxicity (severely compromises organ functi

215 but is not used and, conversely, may lead to unacceptable toxicity and cost to patients if combinatio

216 clax once daily until progressive disease or unacceptable toxicity at target doses from 200 to 1,200

217 of sorafenib used in this trial resulted in unacceptable toxicity for many patients.

218 inued treatment until disease progression or unacceptable toxicity occurred.

219 continued until disease progression or until unacceptable toxicity occurred.

220 ally once daily until disease progression or unacceptable toxicity occurred.

221 se progression while receiving sunitinib, or unacceptable toxicity occurred.

222 , 3 of 4 weeks) as maintenance therapy until unacceptable toxicity or disease progression.

223 enously days 1 through 5 every 3 weeks until unacceptable toxicity or disease progression.

224 sion or treatment discontinuation because of unacceptable toxicity or other protocol-defined reasons,

225 )) was administered weekly for 1 year unless unacceptable toxicity or progression (confirmed on two c

226 ymyxin B as an antiendotoxin strategy has an unacceptable toxicity profile for routine use as an intr

227 administered (45 mg/d) until progression or unacceptable toxicity to patients with recurrent gliobla

228 g every 2 weeks until disease progression or unacceptable toxicity while following established guidel

229 2 weeks (given until disease progression or unacceptable toxicity), or nivolumab plus ipilimumab (1

230 s or until documented disease progression or unacceptable toxicity).

231 m of 5 years or until disease progression or unacceptable toxicity).

232 ays-off schedule) until disease progression, unacceptable toxicity, death, or study discontinuation f

233 irst-line regimen until disease progression, unacceptable toxicity, or administration of a predefined

234 ontinue treatment until disease progression, unacceptable toxicity, or complete remission.

235 r 15 mg/kg every 3 weeks) until progression, unacceptable toxicity, or consent withdrawal.

236 dule for 1 year or until disease recurrence, unacceptable toxicity, or consent withdrawal.

237 ase in 34 (24%) patients and adverse events, unacceptable toxicity, or death in 24 (17%) patients.

238 ent discontinuation owing to adverse events, unacceptable toxicity, or death were collected as a sing

239 supportive care, until disease progression, unacceptable toxicity, or death.

240 tinib (400 mg) once daily until progression, unacceptable toxicity, or other criteria for withdrawal

241 2 weeks until confirmed disease progression, unacceptable toxicity, or other criterion for withdrawal

242 ease progression and clinical deterioration, unacceptable toxicity, or other protocol-defined reasons

243 kg every 2 weeks, until disease progression, unacceptable toxicity, or other protocol-defined reasons

244 eatment continued until disease progression, unacceptable toxicity, or other withdrawal criteria.

245 eatment continued until disease progression, unacceptable toxicity, or patient choice.

246 verolimus 10 mg/d until disease progression, unacceptable toxicity, or patient refusal.

247 (45 mg or 30 mg) until progressive disease, unacceptable toxicity, or patient withdrawal.

248 us loading doses) until disease progression, unacceptable toxicity, or the completion of ten treatmen

249 g/kg every 2 weeks until progression, death, unacceptable toxicity, or withdrawal from study.

250 low-up continuing until disease progression, unacceptable toxicity, or withdrawal of consent.

251 chieve therapeutic benefit in the absence of unacceptable toxicity, providing that route of administr

252 patients discontinuing treatment because of unacceptable toxicity, respectively.

253 g every 2 weeks until disease progression or unacceptable toxicity, whereas patients allocated to ipi

254 d every 21 days until disease progression or unacceptable toxicity, whichever occurred first.

255 reated until they experienced progression or unacceptable toxicity, with follow-up of approximately 2

256 of a 21 day cycle until disease progression, unacceptable toxicity, withdrawal, or death.

257 28-day cycles, until disease progression or unacceptable toxicity.

258 disease progression, patient withdrawal, or unacceptable toxicity.

259 utinib (420 mg) until progressive disease or unacceptable toxicity.

260 e every 3 weeks until disease progression or unacceptable toxicity.

261 tment continued until disease progression or unacceptable toxicity.

262 inistered every 3 weeks until progression or unacceptable toxicity.

263 ily) or placebo until disease progression or unacceptable toxicity.

264 tic targeting attempts have been hampered by unacceptable toxicity.

265 e every 3 weeks until disease progression or unacceptable toxicity.

266 les and treated until disease progression or unacceptable toxicity.

267 -line treatment until disease progression or unacceptable toxicity.

268 kly thereafter) until disease progression or unacceptable toxicity.

269 tinib 420 mg once daily until progression or unacceptable toxicity.

270 as administered until disease progression or unacceptable toxicity.

271 150 mg per day) until disease progression or unacceptable toxicity.

272 tinib orally once daily until progression or unacceptable toxicity.

273 as maintenance until disease progression or unacceptable toxicity.

274 gh 14 of a 21-day cycle until progression or unacceptable toxicity.

275 esponse at 2 months, disease progression, or unacceptable toxicity.

276 ed on treatment until disease progression or unacceptable toxicity.

277 eekly) was administered until progression or unacceptable toxicity.

278 were continued until disease progression or unacceptable toxicity.

279 with gefitinib 250 mg/d until progression or unacceptable toxicity.

280 More potent analogs of SAHA have shown unacceptable toxicity.

281 cell lymphoma, until disease progression or unacceptable toxicity.

282 JAK2 inhibitors until disease progression or unacceptable toxicity.

283 to 2 years or until confirmed progression or unacceptable toxicity.

284 ) every 28 days until disease progression or unacceptable toxicity.

285 dexamethasone (Bd) until disease progression/unacceptable toxicity.

286 , 8, 15, and 22 until progressive disease or unacceptable toxicity.

287 tment continued until disease progression or unacceptable toxicity.

288 0 mg once daily until progressive disease or unacceptable toxicity.

289 nistered orally until disease progression or unacceptable toxicity.

290 erapy that met protocol-defined criteria for unacceptable toxicity.

291 b 3 mg/kg every 2 weeks until progression or unacceptable toxicity.

292 les in the absence of disease progression or unacceptable toxicity.

293 lly) or placebo until disease progression or unacceptable toxicity.

294 avenously every 2 weeks until progression or unacceptable toxicity; postprogression treatment was per

295 t 25 mg/d in relapsed CLL is associated with unacceptable toxicity; the rapid onset and adverse clini

296 be serious challenges and have often led to unacceptable tradeoffs between depth of coverage and sam

297 ck of virological monitoring would result in unacceptable treatment failure misclassification, leadin

298 ions for some of the patients, in particular unacceptable underestimates of the absorbed dose to the

299 mferential resection margin (pCRM) rates and unacceptable variations in permanent colostomies.

300 t avoiding discussions about prognosis is an unacceptable way to maintain hope.